A surprising discovery regarding vitamin B12 could open new possibilities for understanding and potentially treating rare genetic diseases. Researchers have found that the vitamin can correct developmental problems in tiny worms carrying a genetic mutation associated with Verheij syndrome, a rare human disease that causes developmental delays, impaired growth and short stature.
The findings focus on a cellular process called RNA splicing, which helps prepare the genetic instructions that cells use to produce proteins. During splicing, unnecessary parts of the messenger RNA are removed and the remaining sections are brought together in the correct order. When this process goes wrong, it can disrupt essential cellular functions and contribute to serious developmental disorders.
Mutations in genes responsible for splicing can cause conditions such as Verheij syndrome. To better understand the effects of these genetic changes, scientists studied how an associated mutation affects growth and metabolism in a laboratory model.
Vitamin B12 reverses worm development defects
The discovery came from experiments involving C. elegansa small roundworm commonly used in biological research. The researchers were initially looking for previously unknown genes that influence lifespan when they began looking at a mutation in a gene involved in RNA splicing. The same gene is associated with Verheij syndrome in humans.
Worms carrying the mutation developed problems resembling important features of human disease. Their growth slowed considerably and they remained smaller than normal.
To understand why this happened, scientists performed genetic testing and analyzed the worms’ metabolism. They found that the mutation disrupted specific metabolic pathways that depend on vitamin B12 and are essential for healthy growth and normal cellular activity.
The researchers then tested whether supplemental vitamin B12 could counteract these changes. Remarkably, the treatment restored affected metabolic processes to normal and corrected the developmental abnormalities associated with the mutation.
“We were surprised to find that a change in a fundamental RNA processing process had such a targeted effect on vitamin B12-dependent metabolism,” explains Jonathan Kölschbach, first author of the study. “Even more exciting is that we were able to largely correct the consequences of this change in the worm model using vitamin B12.”
Could vitamin B12 help treat a rare genetic disease?
To determine whether their findings could also apply to humans, the researchers examined publicly available datasets of human cells. They also worked with Hormos Dafsari, a pediatric neurologist at Cologne University Hospital, to collect blood samples from patients diagnosed with Verheij syndrome.
These investigations revealed evidence of similar metabolic changes in humans, suggesting that vitamin B12-related pathways affected in worms may also play a role in the human disorder.
Although the results are promising, researchers have not yet established whether vitamin B12 supplementation can improve symptoms in people with Verheij syndrome. Additional studies will be needed to determine whether the benefits observed in the worms can translate into treatment for patients.
The discovery also raises a broader possibility. Metabolic disturbances may contribute more substantially to diseases caused by defective RNA splicing than scientists previously recognized. Understanding these links could help researchers identify new therapeutic strategies, potentially extending beyond Verheij syndrome to other rare genetic diseases.
“Our study is a good example of how basic research in model organisms can provide new insights into human diseases,” says Adam Antebi, director of the Max Planck Institute for the Biology of Aging and lead author of the study. “A fundamental biological question can thus give rise to a new approach that could also become medically relevant in the long term.”
Gn Health
